--- title: "GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share" url: "https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-27" section: "Listings" tickers: "NASDAQ:GOVX" source: "https://www.sec.gov/Archives/edgar/data/832489/000143774926033610/govx20261027_8k.htm" summary: "The board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026," --- By the aibio.space news desk. Sources - [GeoVax Labs (SEC Form 8-K)](https://www.sec.gov/Archives/edgar/data/832489/000143774926033610/govx20261027_8k.htm) - [GeoVax Labs, Inc. 10-K (2026-04-15): business and financial data](https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/govx20251231_10k.htm) [GOVX](https://aibio.space/companies/geovax-labs/) 2026-10-27 # GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share issuance Tickers [GOVX](https://aibio.space/companies/geovax-labs/) The board will pick a reverse split ratio between 1-for-10 and 1-for-25. Holders also approved up to 11,395,256 shares for warrants issued in August 2026, against 9,093,871 shares outstanding at the record date. ## Key facts - **Company**: GeoVax Labs, Inc. (NASDAQ: GOVX) - **News type**: Listings - **Primary source**: [GeoVax Labs (SEC Form 8-K)](https://www.sec.gov/Archives/edgar/data/832489/000143774926033610/govx20261027_8k.htm) *Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The special meeting GeoVax Labs, Inc. (Nasdaq: [GOVX](https://aibio.space/companies/geovax-labs/)) held a special meeting of stockholders on October 27, 2026, according to an 8-K filed the same day under Item 5.07. The company received proxies totaling 4,326,013 of its 9,093,871 issued and outstanding shares, measured at the record date of August 28, 2026. Stockholders approved two proposals. The first proposal approves the issuance of up to 11,395,256 shares of common stock on exercise of warrants held by a certain institutional investor. The 8-K describes that approval as made pursuant to Nasdaq listing rules. The warrants were issued in connection with a warrant exercise inducement that occurred on August 25, 2026. The 8-K does not name the investor, describing it only as a certain institutional investor. The vote was 1,492,403 for, 458,659 against and 44,131 abstaining, with 2,330,820 broker non-votes. The warrant share count is larger than the 9,093,871 shares outstanding at the record date. The votes in favor, at 1,492,403, were a minority of the 4,326,013 proxies received, and 2,330,820 broker non-votes were recorded on the item. ## The reverse split The second proposal amends the certificate of incorporation to allow a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-25. The board of directors will choose the exact ratio. The proposal passed with 3,484,374 votes for, 828,802 against and 12,837 abstaining. The item had no broker non-votes. The opposition to the split, at 828,802 votes, was larger than the opposition to the warrant item, at 458,659. The 8-K gives no ratio and no effective date for the split, so the board's choice and timing are still open. A split at any ratio in that range reduces the number of shares outstanding. It does not change the company's cash or its trial timelines. ## The business and the money GeoVax's 10-K, filed April 15, 2026, describes a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers. Its primary near-term priority is GEO-MVA, a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox. The 10-K says GEO-MVA is intended to address a significant global supply constraint for orthopoxvirus vaccines, and that it is advancing on an expedited regulatory pathway in Europe with plans for a pivotal Phase 3 trial in the second half of 2026. The oncology lead, Gedeptin, recently completed a multicenter Phase 1/2 trial in advanced head and neck cancers. A Phase 2 trial with an immune checkpoint inhibitor is planned to start in the first half of 2027. GEO-CM04S1, a COVID-19 vaccine, is in two Phase 2 trials. For its booster in chronic lymphocytic leukemia, the 10-K describes an interim Data Safety Monitoring Board review, not a completed comparison. Research and development expense was $18.1 million in 2025, down from $23.7 million in 2024. The net loss was $21.5 million in 2025, against $25.0 million in 2024. Cash and cash equivalents were $3.1 million at June 30, 2026, according to its 10-Q, and cash used in operations was $21.5 million in 2025. Stockholders approved the warrant shares and the split after a year with a net loss of $21.5 million, with cash and cash equivalents of $3.1 million at June 30, 2026. The approvals address the share count, not the funding question, and the 10-K's trial plans remain ahead of the company. Votes against were 458,659 on the warrants and 828,802 on the split. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story GOVX GeoVax Labs, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "GeoVax stockholders approve reverse split of up to 1-for-25 and warrant share", 2026-10-27, https://aibio.space/news/geovax-stockholders-approve-reverse-split-up-1-25-warrant-share/